Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel for prevention of tumour-associated epilepsy in grade II-III glioma
ACTRN12617000073303Phase 2Terminated
- Sponsor
- Melbourne Health
- Start
- Nov 2018
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing Perampanel with Placebo (2 arms). Primary endpoints: Time to first seizure after escalation phase and Proportion seizure-free during efficacy assessment phase. Started Nov 2018; status: terminated.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on ACTRN12617000073303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000073303.